clinical trial · NCT07012980
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital·phase2·recruiting·n = 38
Diffuse Large B-Cell LymphomaGlofitamabPolatuzumab VedotinZanubrutinib
brief summary
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
started
Jun 20, 2025
primary completion
Mar 31, 2027
completion
Jul 31, 2027
last updated
Oct 16, 2026
detailed description
This study is a prospective, single-center, interventional, phase 2 study. Each patient screend eligible for this study will receive a combination therapy of glofitamab, zanubrutinib and polatuzumab vedotin.
official title
Efficacy and Safety of Glofitamab, Polatuzumab Vedotin and Zanubrutinib in the First-line Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (DLBCL): A Single-center, Single-arm, Prospective, Phase II Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol